Plus Therapeutics

11/19/2025

CNSide Diagnostics' assay provides accurate, comprehensive data to help clinicians detect and quantify tumor cells.

Learn more about the diagnostic in Healio’s Q&A discussion with Scientific Advisory Board Member, Andrew Brenner, MD, PhD: https://bit.ly/4iarMqm

More about CNSide: cnside-dx.com

In August, Plus Therapeutics announced the launch of the CNSide diagnostic platform, a proprietary, highly sensitive, cerebrospinal fluid (CSF) assay platform performed in a Clinical Laboratory Improvement Amendment accredited laboratory.The platform aims to provides healthcare professionals with ac...

11/19/2025

will present three clinical data updates at the / Society for NeuroOncology’s Meeting this week.

If you’re attending, be sure to stop by CNSide Diagnostics' booth ( #315) and the booth ( #317) to learn more about our latest advancements in .

11/14/2025

' ReSPECT-GBM is a Featured on the American Brain Tumor Association website: https://bit.ly/3JUYRtt

We’re actively recruiting malignant glioma patients who have already gone through standard treatments like surgery, radiation or chemotherapy and have seen their cancer reappear or grow for our Phase 2 study.

Please visit our website to learn more: www.respect-trials.com/gbm

11/10/2025

November is Month, a moment to spread awareness of patients with lung cancer and metastatic lung cancer.

, also know as LM, is most commonly found in patients with melanoma, breast, lung, or gastrointestinal cancer.

is currently undergoing the RESPECT-LM for LM. Learn more and see if you someone you know could be eligible: www.respect-trials.com/lm

CPRIT LUNGevity Foundation LiveLung

11/06/2025

announces its participation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting and Melanoma Research Foundation (MRF) Brain Metastases Summit 4.0 on November 9, 2025 in Alexandria, VA.

Dr. Andrew Brenner, M.D., Ph.D., Professor of Medicine in the Division of Hematology and Oncology at UT Health San Antonio will highlight ’s REYOBIQ and ReSPECT-LM results in the session on (LM) disease.

Learn more: https://bit.ly/496OWeQ

About the enrolling ReSPECT-LM Clinical Trial: www.respect-trials.com/lm

11/05/2025

' President and CEO, Marc Hedrick, MD, joined the pharmaphorum podcast to discuss how ’s advanced platform technologies are developing groundbreaking to treat central nervous system cancers for patients.

Listen to their discussion here: https://bit.ly/47HvgvK

Learn more about our clinical trials here: www.respect-trials.com

CNSide Diagnostics

Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.

11/03/2025

Each year, affects around 110,000 people in the US, yet current treatments are limited and costly.

is addressing this urgent unmet need through two key innovations:
- Reyobiq™ (rhenium [Re186] obisbemeda) is ’s targeted being studied for LM and other CNS cancers
- ™ CSF Assay Platform is CNSide Diagnostics' tool designed to detect tumor cells in cerebrospinal fluid, which is now supported by a national coverage agreement with UnitedHealthcare.

Learn more about our team’s innovations in in The American Journal of Managed Care’s interview article featuring our President and CEO, Dr. Marc Hedrick: https://bit.ly/4hJ5ls0

More about our team’s work: plustherapeutics.com/our-platform

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

10/27/2025

The ' team took part in the 7th Annual Head For The Cure 5K in Phoenix over the weekend in support of research.

Funds raised through this event will locally benefit brain tumor research at Ivy Brain Tumor Center at the Barrow Neurological Institute, Brains for the Cure, and other national brain cancer programs, education, and initiatives.

Thanks to our amazing team for the support of such an important cause!

10/23/2025

’ CEO, Marc Hedrick, M.D., was featured as a key opinion leader in a recent Nature Cancer article by Melanie Senior discussing how companies are advancing next-generation treatments ahead of major data readouts.

“Plus Therapeutics is using rhenium-186, whose 90-hour half-life and 2- to 4-mm beta-radiation pathlength, plus gamma imaging rays, appear ideal for central nervous system cancers including invasive glioblastomas and leptomeningeal metastases, which can be diffuse and tricky to image...The nature of rhenium-186 radiation — with a longer path length than that of alpha emitters, but higher energy than the slower-decaying beta emitter lutetium — may help to overcome brain tissue’s high radioresistance.”

Read the article here: https://go.nature.com/43pNdxi

More about the : https://bit.ly/4hxVXaI

10/21/2025

announces continued operational ex*****on and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostics' Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT).

Recent accomplishments include expansion of the manufacturing footprint, advancements in commercial readiness and appointments in key leadership positions to propel the CNSide diagnostic business forward.

Read more here: bit.ly/42NSCya

More on CNSide here: cnside-dx.com

10/20/2025

10/17/2025

Early detection is one of the keys of preventing and treating (LM) successfully. is extremely proud of the tests our wholly-owned subsidiary, CNSide Diagnostics , is developing to improve the ability to detect and treat LM much earlier.

Learn more about what this could mean for patients in the video from Dr. Seema Nagpal of Stanford Health Care below:

Leptomeningeal disease (LMD) is rare—but it’s one of the hardest complications to detect.
In this clip, Dr. Seema Nagpal of Stanford Health Care explains how it develops, why it’s so challenging to see on MRI, and how new tests like C-Inside and cell-free DNA analysis are changing what’s possible for patients.

Watch now to learn why early detection matters and how awareness empowers care. https://youtu.be/NHKweTH5Fpc